Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Chris Lange | Mar 28, 2016 at 10:55 AM EDT

Apricus Bio Top-Line Results Don’t Stand Up to Expectations

Apricus Biosciences announced top-line results from the Phase 2b proof-of-concept study of fispemifene in men with secondary hypogonadism and sexual…

Chris Lange | Mar 28, 2016 at 10:50 AM EDT

Alder Biopharma Soars on Positive Mid-Stage Trial Results

Alder Biopharmaceuticals announced positive top-line data from two clinical trials evaluating its proprietary monoclonal antibody product candidate for migraine prevention.

Chris Lange | Mar 28, 2016 at 10:05 AM EDT

Tactile Systems Prepares for IPO

Tactile Systems Technology has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering…

Chris Lange | Mar 27, 2016 at 10:25 AM EDT

5 Key Biopharma Movers From Last Week

Over the past week, Akorn, Celator Pharmaceuticals and a few other biotech companies made impressive runs.

Chris Lange | Mar 27, 2016 at 10:05 AM EDT

Top 4 Medtech Picks From Merrill Lynch

Merrill Lynch has some ideas about how to take advantage of the trends in health care going forward.

Chris Lange | Mar 24, 2016 at 11:10 AM EDT

Celator Pharma Prices Secondary Offering

Celator Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) for a secondary offering.

Chris Lange | Mar 24, 2016 at 10:45 AM EDT

Vitae Pharma Prepares for Secondary Offering

Vitae Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) for a secondary offering valued at up to…

Chris Lange | Mar 24, 2016 at 8:50 AM EDT

Portola Pharma Top-Line Results Miss Par for the Course

Portola Pharmaceuticals made waves early on Thursday morning with less than favorable top-line results.

Chris Lange | Mar 23, 2016 at 11:15 AM EDT

Jefferies Identifies 5 Top Biotech Stocks for Huge Upside

Jefferies believes most of the significant biotech downside already occurred, though volatility could continue in the near term.

Chris Lange | Mar 23, 2016 at 9:05 AM EDT

How Ionis Pharma Beat a Biotech Giant

Ionis Pharmaceuticals led biotech stocks early on Wednesday following a key patent dispute win in the U.S. court system.

Chris Lange | Mar 22, 2016 at 11:05 AM EDT

Akorn Back on Track to Restate Results

Akorn reported its preliminary 2015 financial results before the markets opened on Tuesday and issued guidance for the 2016 full…

Chris Lange | Mar 22, 2016 at 8:45 AM EDT

Moleculin Gears Up for IPO

Moleculin Biotech plans to list up to 2 million shares at an estimated $5.50 apiece in an IPO valued at…

Chris Lange | Mar 21, 2016 at 12:15 PM EDT

Why Investors Still Like Celator Pharma Despite a Loss

Celator Pharmaceuticals reported its fourth-quarter financial results before the markets opened on Monday.

Chris Lange | Mar 21, 2016 at 11:40 AM EDT

Advaxis Soars on Positive Survival Results

Advaxis made waves in the markets on Monday following the release of positive data from its most recent study.

Jon C. Ogg | Mar 21, 2016 at 9:50 AM EDT

Why GW Pharma Could More Than Double From Cannabinoid Drugs

What are investors supposed to make of a Bank of America Merrill Lynch call that shows GW Pharmaceuticals worth over…

1 … 217 218 219 220 221 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Apricus Bio Top-Line Results Don’t Stand Up to Expectations

Alder Biopharma Soars on Positive Mid-Stage Trial Results

Tactile Systems Prepares for IPO

5 Key Biopharma Movers From Last Week

Top 4 Medtech Picks From Merrill Lynch

Celator Pharma Prices Secondary Offering

Vitae Pharma Prepares for Secondary Offering

Portola Pharma Top-Line Results Miss Par for the Course

Jefferies Identifies 5 Top Biotech Stocks for Huge Upside

How Ionis Pharma Beat a Biotech Giant

Akorn Back on Track to Restate Results

Moleculin Gears Up for IPO

Why Investors Still Like Celator Pharma Despite a Loss

Advaxis Soars on Positive Survival Results

Why GW Pharma Could More Than Double From Cannabinoid Drugs

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

3 Dividend Stocks Built for Retirement to Buy in June

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

Health and Healthcare Articles

All Health and Healthcare Articles

Apricus Bio Top-Line Results Don’t Stand Up to Expectations

Alder Biopharma Soars on Positive Mid-Stage Trial Results

Tactile Systems Prepares for IPO

5 Key Biopharma Movers From Last Week

Top 4 Medtech Picks From Merrill Lynch

Celator Pharma Prices Secondary Offering

Vitae Pharma Prepares for Secondary Offering

Portola Pharma Top-Line Results Miss Par for the Course

Jefferies Identifies 5 Top Biotech Stocks for Huge Upside

How Ionis Pharma Beat a Biotech Giant

Akorn Back on Track to Restate Results

Moleculin Gears Up for IPO

Why Investors Still Like Celator Pharma Despite a Loss

Advaxis Soars on Positive Survival Results

Why GW Pharma Could More Than Double From Cannabinoid Drugs

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

3 Dividend Stocks Built for Retirement to Buy in June

Featured Reads

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation